Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis.

After 12 days of treatment with different drugs, compared to the model group, the PF-treated hepatoma-bearing mice exhibited a significant reduction in tumor volume and weight (P < 0.05), while the Sor-treated and combination therapy groups showed a highly significant decrease in both tumor volume and weight (P < 0.01).

also in 132,142 other papers